Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia... see more

Recent & Breaking News (PINL:ADXS)

Thinking about buying stock in Aurora Cannabis Inc., Advaxis Inc., Caesars Entertainment Corp., Estre Ambiental Inc., or New Concept Energy Inc.?

PR Newswire April 1, 2019

ADXS-PSA in Combination with KEYTRUDA® Prolonged Survival in Metastatic Castration-Resistant Prostate Cancer

Business Wire April 1, 2019

Preliminary Data from Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity and Clinical Activity

Business Wire March 29, 2019

Advaxis Announces Reverse Stock Split

Business Wire March 28, 2019

Advaxis Granted U.S. Patent Relating to Axalimogene Filolisbac

Business Wire March 25, 2019

Advaxis Reports First Quarter Fiscal 2019 Financial Results and Provides Clinical Pipeline Update

Business Wire March 12, 2019

Advaxis Announces Presentations of ADXS-NEO and ADXS-PSA Data at Upcoming American Association for Cancer Research Annual Meeting

Business Wire March 11, 2019

Advaxis Announces Enrollment of the First Patient in its Phase 1/2 Trial for ADXS-HOT in the Treatment of Non-Small Cell Lung Cancer

Business Wire February 14, 2019

Advaxis Presents an Overview of its Lm Platform and Neoantigen-Directed Programs at the Immuno-Oncology 360° Conference

Business Wire February 6, 2019

New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis — Consolidated Revenues, Company Growth, and Expectations for 2019

GlobeNewswire January 30, 2019

Advaxis to Present an Overview of its Lm Platform and New Information on its Neoantigen-Directed Therapy Programs at the Immuno-Oncology 360° Conference

Business Wire January 28, 2019

Data Highlighting Potential Benefits of Lm Platform Presented at 2019 Keystone Symposia Conference on Cancer Vaccines

Business Wire January 25, 2019

Immunomodulation Bolsters Scientific Advisory Board with Appointments of Robert G. Petit, Ph.D. and Rex Chin-Wei Yung, M.D., F.C.C.P.

GlobeNewswire January 24, 2019

Advaxis’ Phase 3 AIM2CERV Study Placed on Partial Clinical Hold by FDA Related to CMC Requests

Business Wire January 23, 2019

Advaxis Reports Fiscal Year 2018 Financial Results and Provides a Business Update

Business Wire January 10, 2019

Advaxis to Host Business Update Conference Call on January 15, 2019

Business Wire January 8, 2019

Advaxis to Present at LD Micro Main Event

Business Wire November 28, 2018

Advaxis to Present Poster Entitled “Natural Killer (NK) Cells Orchestrate the Antitumor Activities of Listeria monocytogenes (Lm)-Based Immunotherapy” at Society for Immunotherapy of Cancer Annual Meeting

Business Wire November 6, 2018

Advaxis Provides Update on Clinical Pipeline

Business Wire November 2, 2018

Advaxis to Host Business Update Conference Call on November 2, 2018

Business Wire October 26, 2018